Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? by Tara M. Robinson, Ephraim J. Fuchs,

Slides:

Advertisements

Similar presentations

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

Advertisements

Who is the best donor for a related HLA haplotype-mismatched transplant? by Yu Wang, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Xiao-Hui Zhang,

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC),

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin.

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Long-term outcome after bone marrow transplantation for severe aplastic anemia by Lionel Ades, Jean-Yves Mary, Marie Robin, Christèle Ferry, Raphael Porcher,

Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.

CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological.

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis Marie Robin, Federica Giannotti, Eric Deconinck, Mohamad Mohty,

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase by Jiří Pavlů,

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes Junya Kanda, Kazuhiro Ikegame,

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-

Biology of Blood and Marrow Transplantation

Outcome of Transplantation for Myelofibrosis

Chronic graft-versus-host disease

Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia Samer A. Srour, Denái R. Milton,

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Shigeo Fuji,

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation Aline Clavert, Zinaida Peric, Eolia.

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide by Shannon R. McCurdy, Mei-Jie Zhang, Andrew.

Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia John T. Horan,

T Cell–Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an.

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 by Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri,

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study by Salyka Sengsayadeth, Katie.

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Current Graft-versus-Host Disease–Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant Scott R. Solomon,

Bridge to transplant following Bv+Bs regimen.

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells by Yi-Bin Chen, Jennifer Le-Rademacher,

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL by Peter Dreger, Anna Sureda, Kwang.

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone.

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation.

Presentation transcript:

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? by Tara M. Robinson, Ephraim J. Fuchs, Mei-Jie Zhang, Andrew St. Martin, Myriam Labopin, Daniel A. Keesler, Didier Blaise, Asad Bashey, Jean-Henri Bourhis, Fabio Ciceri, Stefan O. Ciurea, Steven M. Devine, Mohamad Mohty, Shannon R. McCurdy, Noel Milpied, Ian K. McNiece, Vanderson Rocha, Rizwan Romee, Gerard Socie, Ibrahim Yakoub-Agha, Robert J. Soiffer, Mary Eapen, and Arnon Nagler BloodAdv Volume 2(11):1180-1186 June 12, 2018 © 2018 by The American Society of Hematology

Tara M. Robinson et al. Blood Adv 2018;2:1180-1186 © 2018 by The American Society of Hematology

Chronic GVHD. (A) The 2-year cumulative incidence of chronic GVHD after transplantation of grafts from haploidentical sibling (42%; 95% CI, 35-50) and HLA-matched sibling (52%; 95% CI, 50-54); P < .001. Chronic GVHD. (A) The 2-year cumulative incidence of chronic GVHD after transplantation of grafts from haploidentical sibling (42%; 95% CI, 35-50) and HLA-matched sibling (52%; 95% CI, 50-54); P < .001. (B) The 2-year cumulative incidence of chronic GVHD after transplantation of grafts from offspring (28%; 95% CI, 20-36) and HLA-matched sibling (46%; 95% CI, 44-49); P < .001. Tara M. Robinson et al. Blood Adv 2018;2:1180-1186 © 2018 by The American Society of Hematology

Nonrelapse mortality. Nonrelapse mortality. (A) The 2-year cumulative incidence of nonrelapse mortality after transplantation of grafts from haploidentical sibling (15%; 95% CI, 10-20) and HLA-matched sibling (13%; 95% CI, 10-15); P = .52. (B) The 2-year cumulative incidence of nonrelapse mortality after transplantation of grafts from offspring (21%; 95% CI, 15-27) and HLA-matched sibling (17%; 95% CI, 14-20); P = .025. Tara M. Robinson et al. Blood Adv 2018;2:1180-1186 © 2018 by The American Society of Hematology

Overall survival. Overall survival. (A) The 2-year probability of overall survival after transplantation of grafts from haploidentical sibling (61%; 95% CI, 54-67) and HLA-matched sibling (61%; 95% CI, 59-63); P = .99. (B) The 2-year probability of overall survival after transplantation of grafts from offspring (44%; 95% CI, 37-51) and HLA-matched sibling (51%; 95% CI, 48-53); P = .003. Tara M. Robinson et al. Blood Adv 2018;2:1180-1186 © 2018 by The American Society of Hematology